Resistance-stabilizing additives for electrolyte

Information

  • Patent Grant
  • 7807300
  • Patent Number
    7,807,300
  • Date Filed
    Tuesday, January 31, 2006
    18 years ago
  • Date Issued
    Tuesday, October 5, 2010
    14 years ago
Abstract
A resistance-stabilizing additive to an electrolyte for a battery cell in an implantable medical device is presented. At least one resistance-stabilizing additive is selected from a group comprising an electron withdrawing group, an aromatic diacid salt, an inorganic salt, an aliphatic organic acid, an aromatic diacid, and an aromatic monoacid.
Description
RELATED APPLICATION

Attention is directed to U.S. patent application Ser. No. 10/366,214 filed Feb. 13, 2003 entitled “Liquid Electrolyte For An Electrochemical Cell,” published as U.S. Pat. Appl. Pub. No. 2004/0161671 on Aug. 19, 2004, which is incorporated herein by reference in its entirety.


FIELD OF THE INVENTION

The present invention generally relates to an electrochemical cell and, more particularly, to an additive in an electrolyte for a battery.


BACKGROUND OF THE INVENTION

Implantable medical devices (IMDs) detect and treat a variety of medical conditions in patients. IMDs include implantable pulse generators (IPGs) or implantable cardioverter-defibrillators (ICDs) that deliver electrical stimuli to tissue of a patient. ICDs typically comprise, inter alia, a control module, a capacitor, and a battery that are housed in a hermetically sealed container. When therapy is required by a patient, the control module signals the battery to charge the capacitor, which in turn discharges electrical stimuli to tissue of a patient.


The battery includes a case, a liner, and an electrode assembly. The liner surrounds the electrode assembly to prevent the electrode assembly from contacting the inside of the case. The electrode assembly comprises an anode and a cathode with a separator therebetween. In the case wall or cover is a fill port or tube that allows introduction of electrolyte into the case. The electrolyte is a medium that facilitates ionic transport and forms a conductive pathway between the anode and cathode. An electrochemical reaction between the electrodes and the electrolyte causes charge to be stored on each electrode. The electrochemical reaction also creates a solid electrolyte interphase (SEI) or passivation film on a surface of an anode such as a lithium anode. The passivation film is ionically conductive and prevents parasitic loss of lithium. However, the passivation film increases internal resistance which reduces the power capability of the battery. It is desirable to reduce internal resistance associated with the passivation film for a battery.





BRIEF DESCRIPTION OF THE DRAWINGS

The present invention will become more fully understood from the detailed description and the accompanying drawings, wherein:



FIG. 1 is a cutaway perspective view of an implantable medical device (IMD);



FIG. 2 is a cutaway perspective view of a battery in the IMD of FIG. 1;



FIG. 3 is an enlarged view of a portion of the battery depicted in FIG. 2 and designated by line 4.



FIG. 4 is a cross-sectional view of an anode and a passivation film;



FIG. 5 is graph that compares discharge and resistance for a conventional and exemplary additive in an electrolyte;



FIG. 6 is graph that compares resistance over time for exemplary additives to an electrolyte;



FIG. 7 is a flow diagram for forming an electrolyte for a battery; and



FIG. 8 is a flow diagram for autoclaving a battery.





DETAILED DESCRIPTION

The following description of embodiments is merely exemplary in nature and is in no way intended to limit the invention, its application, or uses. For purposes of clarity, the same reference numbers are used in the drawings to identify similar elements.


The present invention is directed to an additive for an electrolyte. The additive stabilizes resistance of the battery during storage, thermal processing, and throughout discharge. A resistance-stabilizing additive is defined as one or more chemical compounds, added to an electrolyte, that causes a battery to exhibit low resistance (i.e. generally below 500 ohm centimeter (cm)2) throughout the battery's useful life. In one embodiment, the additive is characterized by an electron withdrawing group. Exemplary chemical compounds containing electron withdrawing group include 2,2,2,-trifluoroacetamide, and benzoyl acetone. In another embodiment, an organic acid serves as a resistance-stabilizing additive. Exemplary organic acids include benzoic acids, carboxylic acids, malic acid, tetramethylammonium (TMA) hydrogen phthalate and hexafluoroglutaric acid.


A battery that includes an exemplary additive may be autoclaved at 125° C. for a half an hour, defined as one cycle, performed three times without adversely affecting the battery. The additives may be used in low, medium, or high capacity batteries.



FIG. 1 depicts an implantable medical device (IMD) 10. IMD 10 includes a case 50, a control module 52, a battery 54 (e.g. organic electrolyte battery) and capacitor(s) 56. Control module 52 controls one or more sensing and/or stimulation processes from IMD 10 via leads (not shown). Battery 54 includes an insulator 58 disposed therearound. Battery 54 charges capacitor(s) 56 and powers control module 52.



FIGS. 2 and 3 depict details of an exemplary organic electrolyte battery 54. Battery 54 includes a case 70, an anode 72, separators 74, a cathode 76, a liquid electrolyte 78, and a feed-through terminal 80. Cathode 76 is wound in a plurality of turns, with anode 72 interposed between the turns of the cathode winding. Separator 74 insulates anode 72 from cathode 76 windings. Case 70 contains the liquid electrolyte 78 to create a conductive path between anode 72 and cathode 76. Electrolyte 78, which includes an additive, serves as a medium for migration of ions between anode 72 and cathode 76 during an electrochemical reaction with these electrodes.


Anode 72 is formed of a material selected from Group IA, IIA or IIIB of the periodic table of elements (e.g. lithium, sodium, potassium, etc.), alloys thereof or intermetallic compounds (e.g. Li—Si, Li—B, Li—Si—B etc.). Anode 72 comprises an alkali metal (e.g. lithium, etc.) in metallic or ionic form.


Cathode 76 may comprise metal oxides (e.g. vanadium oxide, silver vanadium oxide (SVO), manganese dioxide (MnO2) etc.), carbon monofluoride and hybrids thereof (e.g., CFx+MnO2), combination silver vanadium oxide (CSVO) or other suitable compounds.


Electrolyte 78 chemically reacts with anode 72 to form an ionically conductive passivation film 82 on anode 72, as shown in FIG. 4. Electrolyte 78 includes a base liquid electrolyte composition and at least one resistance-stabilizing additive selected from Table 1 presented below. The base electrolyte composition typically comprises 1.0 molar (M) lithium tetrafluoroborate (1-20% by weight), gamma-butyrolactone (50-70% by weight), and 1,2-dimethoxyethane (30-50% by weight). In one embodiment, resistance-stabilizing additives are directed to chemical compounds that include electron withdrawing groups. An exemplary chemical compound with an electron withdrawing group includes 2,2,2-trifluoroacetamide. In another embodiment, the additive is a proton donor such as an organic acid. One type of organic acid is benzoic acid (e.g. 3-hydroxy benzoic acid or 2-4 hydroxy benzoic acid etc.). Every combination of benzoic acid and hydroxyl benzoic acids that exists may be used as a resistance-stabilizing additive composition. Malic acid and tetramethylammonium hydrogen phthalate are other organic acids that may serve as a resistance-stabilizing additive.


Tables 1 and 2 list some exemplary resistance-stabilizing additives. In particular, Table 1 ranks each additive as to its effectiveness with a rank of 1 being the highest or best additive and rank 6 being the lowest ranked additive. Table 1 also briefly describes the time period in which battery 54, which included the specified additive in the electrolyte 78, exhibited resistance-stabilizing characteristics.









TABLE 1







List of exemplary additive resistance-stabilizing additives












Chemical
Exemplary additive




Rank
class
compound
Chemical Structure
Notes





3
Aromatic diacid salts
Tetramethyl- ammonium (TMA) hydrogen phthalate


embedded image


Battery exhibited excellent resistance- stabilizing characteristic during storage Battery exhibited good to neutral resistance- stabilizing characteristic during discharge





6
Inorganic acid salts
Tetrabutyl- ammonium (TBA) hydrogen sulfate


embedded image


Battery exhibited good resistance- stabilizing characteristic during storage Battery exhibited neutral resistance- stabilizing characteristic during discharge





5
Aliphatic organic acids
Phosphonoacetic acid


embedded image


Battery exhibited excellent resistance- stabilizing characteristic during storage Battery exhibited good to neutral resistance- stabilizing characteristic during discharge





1
(*)
2,2,2- Trifluoroacetamide


embedded image


Battery exhibited excellent resistance- stabilizing characteristic during storage and discharge






(*)
Trifluoromethyl vinyl acetate


embedded image


Battery exhibited very good resistance- stabilizing characteristic during discharge





4
Aromatic diacids
Phthalic acid


embedded image


Battery exhibited good resistance- stabilizing characteristic during storage and discharge






(*)
Benzoylacetone


embedded image


Battery exhibited good resistance- stabilizing characteristic during storage and discharge






(*)
Benzoyltrifluoro- acetone


embedded image


Battery exhibited good resistance- stabilizing characteristic during storage and discharge





2
Aromatic mono- acids
Benzoic acid


embedded image


Battery exhibited excellent resistance- stabilizing characteristic during storage and discharge





(*) These compounds include a chemical structure that is characterized by one or more electron-withdrawing groups (e.g. —CF3, —C6H5 located one or two carbon atoms from a double-bonded oxygen atom (i.e. a ketone group)). Additionally, the listed additives may be added to the base electrolyte composition in the range of about 0.001 M to 0.5 M.






Table 2 lists exemplary additive compositions that are mixed with the base electrolyte composition to produce effective resistance-stabilization in battery 54. Effective additive compositions are based upon additives that exhibit superior resistance-stabilizing characteristics either at the beginning of life (BOL) or at the end of life (EOL) of battery 54. In one embodiment, an additive composition comprises a first additive that exhibits substantially superior resistance-stabilizing characteristics at the BOL whereas a second additive exhibits substantially superior resistance-stabilizing characteristics at the EOL. In another embodiment, a first resistance-stabilizing additive exhibits a substantially superior resistance-stabilizing characteristics at the BOL whereas a second resistance-stabilizing additive exhibits average resistance-stabilizing characteristics at the EOL. In still yet another embodiment, a first resistance-stabilizing additive exhibits substantially superior resistance-stabilizing characteristics at the EOL whereas a second resistance-stabilizing additive exhibits average resistance-stabilizing characteristics at the BOL. Generally, each additive is combined with the electrolyte 78 through dissolution or other suitable means.









TABLE 2







Exemplary resistance-stabilizing composition additives










Additive compositions
Quantity of each additive







TMA hydrogen phthalate +
About 0.001 M to about 0.5M



2,2,2-Trifluoroacetamide



TMA hydrogen phthalate +
About 0.001 M to about 0.5M



Trifluoromethyl vinyl acetate



TMA hydrogen phthalate +
About 0.001 M to about 0.5M



Acetone



TMA hydrogen phthalate +
About 0.001 M to about



Xylitol
0.05M



Phosphonoacetic acid +
About 0.001 M to about 0.5M



2,2,2-Trifluoroacetamide



Phosphonoacetic acid +
About 0.001 M to about 0.5M



Trifluoromethyl vinyl acetate



Phosphonoacetic acid +
About 0.001 M to about 0.5M



Acetone



Phosphonoacetic acid +
About 0.001 M to about 0.5M



Xylitol











FIGS. 5-6 graphically depict the resistance-stabilizing superiority of electrolyte 78 over a control electrolyte 88. Electrolyte 78 includes 2,2,2-trifluoroacetamide as the resistance-stabilizing additive and the base electrolyte composition previously described. Control electrolyte 88 is the base electrolyte composition without any additive. Passivation layer 82 initially possesses similar discharge to passivation layer formed by control electrolyte 88. However, later in the discharge (e.g. about 0.90 ampere·hour(Ah)), the passivation layer formed by control electrolyte 88 exhibits resistance that substantially increases. In contrast, electrolyte 78 that includes the additive causes battery 54 to exhibit resistance that remains substantially below the resistance of control electrolyte 88 late in discharge. For example, electrolyte 78 results in battery 54 having 30 ohms lower resistance than control electrolyte 88, as show in FIG. 5.


If the resistance increases in the area between 1 and 1.2 Ah of the curve and IMD 10 records the voltage after a high current event (e.g. telemetry event etc.), a recommended replacement time (RRT) signal may be generated. Preferably, desirable resistance is kept low as long as possible to increase efficiency of battery 54.



FIG. 7 depicts a method for forming a resistance-stabilizing additive composition. At operation 200, a first resistance stabilizing additive is selected. At operation 210, the first resistance stabilizing additive is combined with a second resistance stabilizing additive to create a resistance stabilizing composition.



FIG. 8 depicts a method for autoclaving battery cell 54. Battery cell 54 is inserted into a chamber of an autoclave at operation 300. Battery cell 54 includes an electrolyte and a first resistance-stabilizing additive combined with the electrolyte. At block 310, heat is applied to the chamber of the autoclave. Generally, the autoclaving process occurs at a temperature of 125° C. for a half an hour per cycle. The autoclave cycle is repeated at least three times. After three cycles of autoclaving, battery cell 54 adequately operates.


The following patent application is incorporated by reference in its entirety. Co-pending U.S. patent application Ser. No. 11/343,323 (U.S. Pat. App. Pub. No. 2007/0176151), entitled “ELECTROLYTE ADDITIVE FOR PERFORMANCE STABILITY OF BATTERIES”, filed by Kevin Chen, Donald Merritt and Craig Schmidt on Jan. 31, 2006, and assigned to the same Assignee of the present invention, describes resistance-stabilizing additives for electrolyte.


Although various embodiments of the invention have been described and illustrated with reference to specific embodiments thereof, it is not intended that the invention be limited to such illustrative embodiments. For example, while an additive composition is described as a combination of two additives, it may also include two or more additives selected from Table 1. The description of the invention is merely exemplary in nature and, thus, variations that do not depart from the gist of the invention are intended to be within the scope of the invention. Such variations are not to be regarded as a departure from the spirit and scope of the invention.

Claims
  • 1. An electrolyte comprising a base liquid electrolyte composition and a resistance-stabilizing additive, wherein the resistance-stabilizing additive comprises a compound comprising an electron-withdrawing group that is selected from one of trifluoromethylvinyl acetate and 2,2,2-trifluoroacetamide.
  • 2. An electrolyte comprising a base liquid electrolyte composition and a resistance-stabilizing additive, wherein the resistance-stabilizing additive comprises 2,2,2-trifluoroacetamide.
  • 3. An electrolyte comprising: a base liquid electrolyte composition;a first resistance-stabilizing additive; anda second resistance-stabilizing additive combined with the first resistance-stabilizing additive;wherein the first resistance-stabilizing additive comprises 2,2,2-trifluoroacetamide.
  • 4. The electrolyte of claim 3, wherein second resistance-stabilizing additive comprises at least one of TMA hydrogen phthalate, TBA hydrogen sulfate, phosphonoacetic acid, trifluoromethyl vinyl acetate, phthalic acid, benzoylacetone, benzoyltrifluoroacetone, and benzoic acid.
  • 5. The electrolyte of claim 4, further comprising: a third resistance-stabilizing additive, the third resistance-stabilizing additive being different from the first and second resistance-stabilizing additives and comprising at least one of TMA hydrogen phthalate, TBA hydrogen sulfate, phosphonoacetic acid, trifluoromethyl vinyl acetate, phthalic acid, benzoylacetone, benzoyltrifluoroacetone, and benzoic acid.
  • 6. A method for forming an electrolyte in a battery cell for an implantable medical device, the method comprising: selecting a first resistance-stabilizing additive;combining a second resistance-stabilizing additive with the first resistance-stabilizing additive to form a resistance-stabilizing composition; andcombining the resistance-stabilizing composition with a base electrolyte composition for the battery cell;wherein the first resistance-stabilizing additive comprises 2,2,2-trifluoroacetamide.
  • 7. The method of claim 6, wherein the second resistance-stabilizing additive comprises at least one of TMA hydrogen phthalate, TBA hydrogen sulfate, phosphonoacetic acid, trifluoromethyl vinyl acetate, phthalic acid, benzoylacetone, benzoyltrifluoroacetone, and benzoic acid.
  • 8. A battery comprising an electrode assembly and an electrolyte, wherein the electrolyte comprises a liquid electrolyte and a resistance-stabilizing additive, wherein the resistance-stabilizing additive comprises trifluoromethylvinyl acetate, 2,2,2-trifluoroacetamide, or combinations thereof.
  • 9. The battery of claim 8, wherein the resistance-stabilizing additive comprises 2,2,2-trifluoroacetamide.
  • 10. An implantable medical device comprising the battery of claim 9.
  • 11. The battery of claim 8, wherein the resistance-stabilizing additive comprises trifluoromethyl vinyl acetate.
  • 12. An implantable medical device comprising the battery of claim 11.
  • 13. A battery comprising an electrode assembly and an electrolyte, wherein the electrolyte comprises a liquid electrolyte and a resistance-stabilizing additive composition, the additive composition comprising: a first resistance-stabilizing additive; anda second resistance-stabilizing additive combined with the first resistance-stabilizing additive;wherein the first resistance-stabilizing additive comprises 2,2,2-trifluoroacetamide.
  • 14. The battery of claim 13, wherein the second resistance-stabilizing additive comprises at least one of TMA hydrogen phthalate, TBA hydrogen sulfate, phosphonoacetic acid, trifluoromethyl vinyl acetate, phthalic acid, benzoylacetone, benzoyltrifluoroacetone, and benzoic acid.
  • 15. An implantable medical device comprising the battery of claim 13.
  • 16. An electrolyte comprising: a base liquid electrolyte composition;a first resistance-stabilizing additive; anda second resistance-stabilizing additive combined with the first resistance-stabilizing additive;wherein the first resistance-stabilizing additive comprises trifluoromethyl vinyl acetate.
  • 17. The electrolyte of claim 16, wherein the second resistance-stabilizing additive comprises at least one of TMA hydrogen phthalate, TBA hydrogen sulfate, phosphonoacetic acid, 2,2,2-trifluoroacetamide, phthalic acid, benzoylacetone, benzoyltrifluoroacetone, and benzoic acid.
  • 18. The electrolyte of claim 17, further comprising: a third resistance-stabilizing additive, the third resistance-stabilizing additive being different from the first and second resistance-stabilizing additives and comprising at least one of TMA hydrogen phthalate, TBA hydrogen sulfate, phosphonoacetic acid, 2,2,2-trifluoroacetamide, phthalic acid, benzoylacetone, benzoyltrifluoroacetone, and benzoic acid.
  • 19. A method for forming an electrolyte in a battery cell for an implantable medical device, the method comprising: selecting a first resistance-stabilizing additive;combining a second resistance-stabilizing additive with the first resistance-stabilizing additive to form a resistance-stabilizing composition; andcombining the resistance-stabilizing composition with a base electrolyte composition for the battery cell;wherein the first resistance-stabilizing additive comprises trifluoromethyl vinyl acetate.
  • 20. The method of claim 19, wherein the second resistance-stabilizing additive comprises at least one of TMA hydrogen phthalate, TBA hydrogen sulfate, phosphonoacetic acid, 2,2,2-trifluoroacetamide, phthalic acid, benzoylacetone, benzoyltrifluoroacetone, and benzoic acid.
  • 21. A battery comprising an electrode assembly and an electrolyte, wherein the electrolyte comprises a liquid electrolyte and a resistance-stabilizing additive composition, the additive composition comprising: a first resistance-stabilizing additive; anda second resistance-stabilizing additive combined with the first resistance-stabilizing additive;wherein the first resistance-stabilizing additive comprises trifluoromethyl vinyl acetate.
  • 22. The battery of claim 21, wherein the second resistance-stabilizing additive comprises at least one of TMA hydrogen phthalate, TBA hydrogen sulfate, phosphonoacetic acid, 2,2,2-trifluoroacetamide, phthalic acid, benzoylacetone, benzoyltrifluoroacetone, and benzoic acid.
  • 23. An implantable medical device comprising the battery of claim 21.
US Referenced Citations (100)
Number Name Date Kind
3423242 Meyers Jan 1969 A
4310609 Liang et al. Jan 1982 A
4391729 Liang et al. Jul 1983 A
4398346 Underhill et al. Aug 1983 A
4447346 MacNamee et al. May 1984 A
4469610 Fukuda et al. Sep 1984 A
4715976 Mori et al. Dec 1987 A
4860169 Dapo Aug 1989 A
4894302 Hoffman et al. Jan 1990 A
4957833 Daifuku et al. Sep 1990 A
4964877 Keister et al. Oct 1990 A
4975806 Clouse Dec 1990 A
5017444 Nakajima et al. May 1991 A
5144949 Olson Sep 1992 A
5147737 Post et al. Sep 1992 A
5154992 Berberick et al. Oct 1992 A
5158078 Bennett et al. Oct 1992 A
5175066 Hamwi et al. Dec 1992 A
5175674 Dapo Dec 1992 A
5180642 Weiss et al. Jan 1993 A
5221453 Crespi Jun 1993 A
5250373 Muffoletto et al. Oct 1993 A
5260145 Armand et al. Nov 1993 A
5273840 Dominey Dec 1993 A
5306581 Taylor et al. Apr 1994 A
5312453 Shelton et al. May 1994 A
5312458 Muffoletto et al. May 1994 A
5342409 Mullett Aug 1994 A
5434017 Berkowitz et al. Jul 1995 A
5437692 Dasgupta et al. Aug 1995 A
5439760 Howard et al. Aug 1995 A
5468569 Pyszczek et al. Nov 1995 A
5472810 Takeuchi et al. Dec 1995 A
5496481 Liu Mar 1996 A
5498494 Takeuchi et al. Mar 1996 A
5507966 Liu Apr 1996 A
5549717 Takeuchi et al. Aug 1996 A
5550706 Kurzweil et al. Aug 1996 A
5558680 Takeuchi et al. Sep 1996 A
5677086 Satoh et al. Oct 1997 A
5695892 Leising et al. Dec 1997 A
5716729 Sunderland et al. Feb 1998 A
5744258 Bai et al. Apr 1998 A
5753389 Gan et al. May 1998 A
5766797 Crespi et al. Jun 1998 A
5776635 Gan et al. Jul 1998 A
5895733 Crespi et al. Apr 1999 A
5955218 Crespi et al. Sep 1999 A
5962720 Gan et al. Oct 1999 A
5989748 Nagasubramanian Nov 1999 A
6006133 Lessar et al. Dec 1999 A
6017656 Crespi et al. Jan 2000 A
6030720 Chu et al. Feb 2000 A
6057062 Gan et al. May 2000 A
6093506 Crespi et al. Jul 2000 A
6130005 Crespi et al. Oct 2000 A
6136477 Gan et al. Oct 2000 A
6150057 Takeuchi Nov 2000 A
6153338 Gan et al. Nov 2000 A
6174629 Gan et al. Jan 2001 B1
6180283 Gan et al. Jan 2001 B1
6200701 Gan et al. Mar 2001 B1
6203942 Gan et al. Mar 2001 B1
6210839 Gan et al. Apr 2001 B1
6221534 Takeuchi et al. Apr 2001 B1
6265106 Gan et al. Jul 2001 B1
6274269 Gan et al. Aug 2001 B1
6350542 Gan et al. Feb 2002 B1
6350546 Gan et al. Feb 2002 B1
6403256 Gan et al. Jun 2002 B1
6444360 Gan et al. Sep 2002 B2
6451483 Probst et al. Sep 2002 B1
6495285 Gan et al. Dec 2002 B2
6522524 Feger et al. Feb 2003 B1
6551747 Gan Apr 2003 B1
6562255 Feger May 2003 B1
6587329 Feger Jul 2003 B1
6630272 Iwamoto et al. Oct 2003 B1
6743370 Feger et al. Jun 2004 B1
6744619 Feger Jun 2004 B1
6783888 Gan et al. Aug 2004 B2
6942819 Ebel et al. Sep 2005 B2
7225035 Brabec et al. May 2007 B2
20020012844 Gan et al. Jan 2002 A1
20020192562 Ferreira et al. Dec 2002 A1
20030190531 Otsuki et al. Oct 2003 A1
20040012370 Miller Jan 2004 A1
20040029005 Leising et al. Feb 2004 A1
20040161671 Merritt et al. Aug 2004 A1
20050117276 Liu et al. Jun 2005 A1
20050180094 Muffoletto et al. Aug 2005 A1
20060099495 Suzuki et al. May 2006 A1
20060166078 Chen et al. Jul 2006 A1
20070077488 Chen et al. Apr 2007 A1
20070176151 Chen et al. Aug 2007 A1
20070178371 Merritt et al. Aug 2007 A1
20070178378 Merritt et al. Aug 2007 A1
20070178381 Howard et al. Aug 2007 A1
20070275284 Merritt et al. Nov 2007 A1
20090181302 Chen et al. Jul 2009 A1
Foreign Referenced Citations (29)
Number Date Country
0 885 874 May 1998 EP
0 885 874 May 1998 EP
0 918 364 Oct 1998 EP
0 918 364 Oct 1998 EP
1 109 244 Jun 2001 EP
1 156 541 Nov 2001 EP
1 176 659 Jan 2002 EP
1193781 Apr 2002 EP
1 207 568 May 2002 EP
1 156 541 Mar 2003 EP
1 313 159 May 2003 EP
1 331 683 Jul 2003 EP
1 313 159 Apr 2004 EP
1 207 568 Aug 2005 EP
1 331 683 Aug 2005 EP
2-154411 Jun 1990 JP
2-156620 Jun 1990 JP
02156620 Jun 1990 JP
4-304612 Oct 1992 JP
04304612 Oct 1992 JP
8-335533 Dec 1996 JP
08335533 Dec 1996 JP
2001176548 Jun 2001 JP
2002170569 Jun 2002 JP
02154411 Aug 2007 JP
WO 0036683 Jun 2000 WO
WO 0036683 Jun 2000 WO
WO 03021707 Mar 2003 WO
WO2004075332 Sep 2004 WO
Related Publications (1)
Number Date Country
20070178378 A1 Aug 2007 US